Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Toshifumi TadaTakashi KumadaAtsushi HiraokaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraTakeshi HatanakaSatoru KakizakiNoritomo ShimadaKazuhito KawataFujimasa TadaHideko OhamaKazuhiro NousoAsahiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiHisashi KosakaAtsushi NaganumaYohei KoizumiShinichiro NakamuraMasaki KaiboriHiroko IijimaYoichi HiasaPublished in: Cancer medicine (2022)
Treatment-related hypertension is associated with good outcomes in patients with HCC treated with Atez/Bev.